BioHub Maryland recently announced a significant development in its mission to bolster the biopharma workforce within the state. Securing a $75,000 grant under the EARN Maryland program, an initiative supported by the Maryland Department of Labor, the organization will use these funds to train
Eli Lilly is making a bold move to shape the future of pharmaceutical manufacturing with its $4.5 billion investment in the Lilly Medicine Foundry. This new facility, set to open in late 2027 in Lebanon, Indiana's LEAP Research and Innovation District, is poised to redefine how the industry
The U.S. government, through the Centers for Medicare and Medicaid Services (CMS), has unveiled fresh modifications to its drug price negotiation process under Medicare. These changes aim to enhance transparency and efficacy as the second round of talks with pharmaceutical manufacturers looms on
Over the next three months, the U.S. Food and Drug Administration (FDA) will be issuing several pivotal decisions that could significantly impact the biopharma market. In particular, FDA approvals are pending for five critical drugs from companies such as BridgeBio Pharma, AstraZeneca, Daiichi
The biopharmaceutical contract research organization (CRO) market is experiencing transformative growth, driven by rapid technological advancements and evolving consumer demands. Understanding these trends is essential for stakeholders looking to navigate and capitalize on this dynamic industry.
The biopharmaceutical industry is a dynamic and complex sector that has seen exponential growth over recent years. Central to this growth is the practice of outsourcing various elements of the biopharma process, from raw material sourcing to finished drug development. This article delves into how
